About Mekonos
Mekonos is a company based in Palo Alto (United States) founded in 2016 by Greg Sitters, Steven Banerjee, and Anil Narasimha. Mekonos has raised $29.6 million across 2 funding rounds from investors including Novartis, Debiopharm and Magnetar Capital. Mekonos operates in a competitive market with competitors including StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Sixfold Bioscience, among others.
- Headquarter Palo Alto, United States
- Founders Greg Sitters, Steven Banerjee, Anil Narasimha
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$29.6 M (USD)
in 2 rounds
-
Latest Funding Round
$25 M (USD), Series A
Nov 09, 2021
-
Investors
Novartis
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Mekonos
Unlock access to complete
Systems Team
1 people
Sr. Team
1 people
Co Team
1 people
Creative and Marketing Team
1 people
Senior Team
1 people
Unlock access to complete
Funding Insights of Mekonos
Mekonos has successfully raised a total of $29.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $25 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mekonos
Mekonos has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Debiopharm and Magnetar Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Magnetar Capital is engaged in alternative asset management.
|
Locked | Locked | Locked | |
|
Early-stage tech startups are invested in globally by TDK Ventures.
|
Locked | Locked | Locked | |
|
Investment firm focused on finance and technology opportunities.
|
Locked | Locked | Locked |
Investor details for Mekonos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mekonos
Investment portfolio details for Mekonos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mekonos
Detailed financials for Mekonos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mekonos Comparisons
Peer comparison for Mekonos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mekonos
Mekonos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Sixfold Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AAV-based gene therapies for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| Locked | Locked | Locked |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Oligonucleotide delivery systems are developed for targeted gene therapy.
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
Detailed competitors of Mekonos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mekonos
Complete news archive for Mekonos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mekonos
Mekonos was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Mekonos is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Steven Banerjee is the current CEO of Mekonos. They have also founded this company.
Mekonos is a funded company, having raised a total of $29.6M across 2 funding rounds to date.
Mekonos was founded in 2016 and is based in Palo Alto, United States. Nanorobotic chips made from silicon are developed by the company for use in cell engineering. Biomolecules are delivered to cells via these chips to enable genetic modifications. The technology supports cell therapy processes, particularly for cancer treatment, within the biotechnology sector. Operations focus on advancing nanorobotics for therapeutic applications.
Mekonos's top competitors include Phase Genomics, Genedit and CellFE.
Mekonos has 14 investors. Key investors include Novartis, Debiopharm, Magnetar Capital, TDK Ventures, and Sands Capital.